| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4216106 | Revue des Maladies Respiratoires Actualités | 2011 | 4 Pages |
Abstract
International recommendations assume that is proposed, after a first line containing a platinum salt, a second-line treatment for patients who maintained a good performance status. This treatment may appeal to docetaxel to pemetrexed or erlotinib. Several avenues are opened for the third exacerbation. It is recommended to propose the inclusion in a clinical trial.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
L. Teixeira, L. Staudacher, E. Kempf, C. Durand, G. Bussac, J.-L. Jagot, C. Beuzelin, S. Salmeron, J. Trédaniel,